前沿生物跌2.67% A股募20亿瑞银证券保荐上市

Core Viewpoint - Frontline Bio (688221.SH) is currently experiencing a decline in stock price, closing at 14.20 yuan with a drop of 2.67%, indicating a state of underperformance since its IPO [1] Group 1: IPO and Stock Performance - Frontline Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an initial public offering (IPO) price of 20.50 yuan per share [1] - The stock reached its highest price of 35.53 yuan on the first day of trading, marking the peak since its listing [1] - The total number of shares issued during the IPO was 89.96 million, accounting for 25.01% of the total shares post-issuance [1] Group 2: Fundraising and Use of Proceeds - The total amount raised from the IPO was 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [1] - The company planned to use the raised funds for various projects, including the clinical development of an HIV fusion inhibitor, a combined therapy, a new transdermal analgesic patch, marketing network construction, and to supplement working capital [1] - The total fundraising from two rounds of issuance amounts to 2.044 billion yuan [4] Group 3: Underwriting and Strategic Investment - UBSAG, the underwriting institution, participated in the strategic placement of the IPO, acquiring 2,926,829 shares, which is 3.25% of the total issuance, for approximately 60 million yuan [2] - The lock-up period for the shares acquired by UBSAG is set for 24 months from the date of listing [2] Group 4: Subsequent Issuance - On September 22, 2022, Frontline Bio announced a specific issuance of 14,818,653 shares at a price of 13.51 yuan per share, raising a total of approximately 200.2 million yuan [3] - After deducting issuance costs, the net amount raised from this issuance was approximately 195.67 million yuan [3]